ISRCTN18067579已完成1 期
Pharmacokinetic study of a novel lipid formulation of cannabidiol (CBD) compared to a standard formulation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 13/04/2022:
- •1. Healthy volunteers. Defined as healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine.
- •2. Aged 18-45 years
- •3. Agree to fast 15 hours, i.e. 10 pm to 1 pm on dosing days
- •4. Capable of giving informed consent
- •5. Written informed consent from participant
- •Previous inclusion criteria:
- •1. Healthy volunteers
- •2. Age 18-45 years
- •3. Females of childbearing potential and males must be willing to use highly effective method of contraception (hormonal or barrier method of birth control; abstinence) throughout the duration of the study and for at least 4 weeks after
- •4. Agreeing to fast 15 hours; 10pm-1pm on dosing days
- •5. Capable of giving informed consent
- •6. Written informed consent from participant
排除标准
- •Current exclusion criteria as of 13/04/2022:
- •1. Clinically relevant medical history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the participant
- •2. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer’s participation in the trial or make it unnecessarily hazardous
- •3. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, or history of any neurological or mental illness
- •4. Surgery or medical condition that might affect absorption of medicines
- •5. Blood pressure and heart rate in supine position at the screening examination outside the following ranges. Repeat measurements are permitted if values are borderline (i.e. values that are within 5 mm Hg for blood pressure or 5 beats/min for heart rate) or if requested by the investigator. Subjects can be included if the repeat value is within range or still borderline but deemed not clinically significant by the investigator.
- •5.1. Blood pressure 90–140 mm Hg systolic, 40–90 mm Hg diastolic
- •5.2. Heart rate 40–100 beats/min
- •6. Loss of more than 400 ml blood during the 3 months before the trial, e.g. as a blood donor
- •7. Any prescribed medication (apart from contraceptives)
- •8. Use of any CBD products within 6 months of IMP administration
- •9. Use of any over-the-counter medications or health supplements within the past 2 weeks
- •10. BMI <18 or >30 kg/m2
- •11. History of alcohol or substance misuse disorder
- •12. Intake of more than 14 units of alcohol weekly.
- •13. Smokes more than 10 cigarettes per day
- •14. Use of any illicit substances within the last 6 months
- •15. Pregnant or breastfeeding
- •16. Women of childbearing potential (as defined in CTFG guidelines, see 5.7 Concomitant Medication) not willing to use a highly effective form of contraception (as defined in CTFG guidelines, see section 5.7 Concomitant Medication) during participation in the study or male patients not willing to ensure use of a condom during participation in the study
- •17. eGFR =70 ml/min
- •18. Any liver function or renal function test abnormality. A repeat is allowed on one occasion for determination of eligibility.
- •19. Urine drug screen positive for any substances
- •20. Positive alcohol breath test
- •21. Participant in any other clinical trial or experimental drug study in the past 3 months
- •22. Known hypersensitivity to CBD and/or SEEK formulation excipients
- •23. Not able to swallow capsules
- •Previous exclusion criteria:
- •1. Any prescribed medication (apart from contraceptives)
- •2. Use of any CBD products within six months of IMP administration
- •3. Use of any over-the-counter medications or health supplements within the past 2 weeks
- •4. BMI <18 or >30.0 kg/m²
- •5. History of alcohol or substance misuse disorder
- •6. Smokes more than 10 cigarettes per day
- •7. Use of any illicit subs
研究者
相似试验
已完成
不适用
Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) PatientsCystic FibrosisNCT02646995Société des Produits Nestlé (SPN)16
进行中（未招募）
1 期
A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancyEUCTR2006-006297-23-GBGuy's & St Thomas' NHS Foundation Trust10
已完成
不适用
Pharmacokinetic study of a new formulation of elacridargezonde vrijwiliggersNL-OMON38922Antoni van Leeuwenhoek Ziekenhuis12
进行中（未招募）
1 期
Pharmakokinetik von lipid-formuliertem Amphotericin B unter Albumindialyse(Pharmacokinetics of lipid-formulated amphotericin B during albumin dialysis) - Amphotericin B in Albumin dialysisPlasma concentrations of lipidformulated amphotericin B will be measured in patients requiring treatment with lipid-formulated amphotericin B for systemic fungal infection (proven or suspected) and impaired renal function as well as albumin dialysis for cholestatic liver failure.EUCTR2005-003406-28-ATMedical University, Dpt. Internal Medicin, Division of General Inteal Medicine12
已完成
2 期
Effect of tretinoin nano lipid on acneacne.Acne vulgarisIRCT20161207031288N2Jarfandishan-e Navid-e Salamat (Janus) knowledge-based company20